BRPI1013992A2 - composições e métodos para o tratamento de resistência à insulina e diabetes melito - Google Patents
composições e métodos para o tratamento de resistência à insulina e diabetes melitoInfo
- Publication number
- BRPI1013992A2 BRPI1013992A2 BRPI1013992A BRPI1013992A BRPI1013992A2 BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2 BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- diabetes mellitus
- insulin resistance
- treating insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17313409P | 2009-04-27 | 2009-04-27 | |
| PCT/US2010/032620 WO2010126908A1 (en) | 2009-04-27 | 2010-04-27 | Compositions and methods for treating insulin resistance and diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013992A2 true BRPI1013992A2 (pt) | 2016-08-16 |
Family
ID=43032520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013992A BRPI1013992A2 (pt) | 2009-04-27 | 2010-04-27 | composições e métodos para o tratamento de resistência à insulina e diabetes melito |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2424507A4 (es) |
| JP (2) | JP2012525396A (es) |
| CN (1) | CN102413817B (es) |
| AU (1) | AU2010241736B2 (es) |
| BR (1) | BRPI1013992A2 (es) |
| CA (1) | CA2758738A1 (es) |
| IL (1) | IL215925A0 (es) |
| MX (1) | MX2011011333A (es) |
| WO (1) | WO2010126908A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| CA3045436A1 (en) | 2009-01-29 | 2010-08-05 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| JP5907966B2 (ja) | 2010-08-05 | 2016-04-26 | フォーサイト・ビジョン フォー・インコーポレーテッド | 埋め込み型治療デバイス |
| WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
| US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
| AU2011289172B2 (en) | 2010-08-12 | 2015-09-24 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
| KR102117282B1 (ko) * | 2010-11-15 | 2020-06-01 | 베링거 인겔하임 인터내셔날 게엠베하 | 혈관보호성 및 심장보호성 항당뇨 치료요법 |
| US9034883B2 (en) * | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| US20120263764A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
| WO2013003620A2 (en) | 2011-06-28 | 2013-01-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
| EP3903733A1 (en) | 2011-09-16 | 2021-11-03 | ForSight Vision4, Inc. | Fluid exchange apparatus |
| WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| JP6159584B2 (ja) * | 2012-06-14 | 2017-07-05 | 松本 高明 | 輸液、輸液の製造方法および輸液装置 |
| CH706747A2 (de) * | 2012-07-17 | 2014-01-31 | Hanspeter Steffen | Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser. |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| CA2907681C (en) | 2013-03-28 | 2022-11-22 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| US20170056438A1 (en) * | 2014-10-17 | 2017-03-02 | Aqua Zest Corporation | Nanobubble-containing composition and use thereof |
| WO2015099201A1 (ja) * | 2013-12-27 | 2015-07-02 | アクア・ゼスト株式会社 | ナノバブル含有組成物およびその用途 |
| RU2695563C2 (ru) | 2014-07-15 | 2019-07-24 | Форсайт Вижн4, Инк. | Способ и устройство для доставки глазного имплантата |
| US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| CN114587774A (zh) | 2014-11-10 | 2022-06-07 | 弗赛特影像4股份有限公司 | 治疗眼睛的*** |
| JP6674748B2 (ja) * | 2015-05-27 | 2020-04-01 | 花王株式会社 | Ｇｌｐ−１分泌促進剤 |
| KR20180084104A (ko) | 2015-11-20 | 2018-07-24 | 포사이트 비젼4, 인크. | 연장 방출 약물 전달 장치를 위한 다공성 구조물 |
| AR108177A1 (es) | 2016-04-05 | 2018-07-25 | Forsight Vision4 Inc | Dispositivos de suministro de fármacos oculares implantables |
| CN105878194A (zh) * | 2016-06-07 | 2016-08-24 | 沈阳药科大学 | 一种格列本脲纳米结晶制剂及其制备方法 |
| CN106362166B (zh) * | 2016-10-27 | 2019-12-10 | 武汉大学 | 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
| BR112020010053A2 (pt) | 2017-11-21 | 2020-11-03 | Forsight Vision4, Inc. | aparelho para troca de fluido para sistema de liberação de porta expansível e métodos de uso do mesmo |
| CN110006871A (zh) * | 2019-02-20 | 2019-07-12 | 常州大学 | 一个基于外源性组胺检测的细胞模型以及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992005792A1 (de) * | 1990-10-02 | 1992-04-16 | Buchholz Klaus L | Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung |
| US7196164B2 (en) * | 1997-07-08 | 2007-03-27 | Human Genome Sciences, Inc. | Secreted protein HHTLF25 |
| US6861227B2 (en) * | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| US6649145B2 (en) * | 2001-02-01 | 2003-11-18 | Hydron Technologies, Inc. | Compositions and method of tissue superoxygenation |
| US6902902B2 (en) * | 2001-11-27 | 2005-06-07 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders |
| US20060275200A1 (en) * | 2005-06-03 | 2006-12-07 | BAGLEY David | Method for structuring oxygen |
| AU2007308838B2 (en) * | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| AU2007308840C1 (en) * | 2006-10-25 | 2014-09-25 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| US20080154795A1 (en) * | 2006-12-25 | 2008-06-26 | Amos Alon | Auction platform and applications |
| JP2008156320A (ja) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
-
2010
- 2010-04-27 CA CA2758738A patent/CA2758738A1/en not_active Abandoned
- 2010-04-27 WO PCT/US2010/032620 patent/WO2010126908A1/en active Application Filing
- 2010-04-27 CN CN201080018429.3A patent/CN102413817B/zh not_active Expired - Fee Related
- 2010-04-27 JP JP2012508605A patent/JP2012525396A/ja active Pending
- 2010-04-27 MX MX2011011333A patent/MX2011011333A/es active IP Right Grant
- 2010-04-27 EP EP10770213A patent/EP2424507A4/en not_active Withdrawn
- 2010-04-27 BR BRPI1013992A patent/BRPI1013992A2/pt active Search and Examination
- 2010-04-27 AU AU2010241736A patent/AU2010241736B2/en not_active Ceased
-
2011
- 2011-10-25 IL IL215925A patent/IL215925A0/en unknown
-
2015
- 2015-08-31 JP JP2015170249A patent/JP2015229678A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010241736B2 (en) | 2016-01-28 |
| EP2424507A1 (en) | 2012-03-07 |
| IL215925A0 (en) | 2011-12-29 |
| AU2010241736A1 (en) | 2011-12-22 |
| CA2758738A1 (en) | 2010-11-04 |
| CN102413817A (zh) | 2012-04-11 |
| MX2011011333A (es) | 2011-11-18 |
| EP2424507A4 (en) | 2012-10-24 |
| CN102413817B (zh) | 2014-12-17 |
| JP2012525396A (ja) | 2012-10-22 |
| JP2015229678A (ja) | 2015-12-21 |
| WO2010126908A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013992A2 (pt) | composições e métodos para o tratamento de resistência à insulina e diabetes melito | |
| BRPI0910282A2 (pt) | Composto oxadiazo-antraceno para o tratamento de diabetes | |
| BRPI0716134A2 (pt) | tratamento de combinaÇço para diabetes mellitus | |
| BRPI1012642A2 (pt) | formulação de insulina e método para o tratamento de um indivíduo diabético. | |
| BRPI0911782A2 (pt) | composição de insulina de ação super rápida | |
| BRPI0908416A2 (pt) | Seringa para injeção | |
| FI20096188A0 (fi) | Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle | |
| DK2252312T3 (da) | Fremgangsmåder til forebyggelse eller behandling af insulinresistens | |
| DK3181134T3 (da) | Bifidobakterier til behandling af diabetes og relaterede tilstande | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BRPI1006145A2 (pt) | "composição e método para tratamento de diabetes". | |
| BRPI0813909A2 (pt) | Seringa com mecanismo de inutilização | |
| IL205554A (en) | An insulin resistance treatment containing melanocortin | |
| BRPI0815760A2 (pt) | Composição dermatológica injetável para o tratamento de rugas | |
| BRPI0919288A2 (pt) | teriapia de combinação para tratamento de diabetes e condições relacionadas. | |
| BRPI0822830A2 (pt) | Seringa com mecanismo de desativação | |
| EP2120959A4 (en) | METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA | |
| BRPI0906094A2 (pt) | composto e método de tratamento de diabetes do tipo ii | |
| BRPI0911083A8 (pt) | métodos para o tratamento ou prevenção da diabetes mellitus e outros desequilíbrios metabólicos | |
| BRPI0806964A2 (pt) | Combinações de agonístico beta-2-adrenoceptor e benzotiazolona | |
| SI2403605T1 (sl) | Sestavki, ki obsegajo aP2-specifično protitelo ali njegov fragment, za uporabo pri zdravljenju diabetesa, intolerance za glukozo ali z debelostjo povzročene inzulinske rezistence | |
| BR112012006437A2 (pt) | composições e métodos para tratamento do diabetes e outros distúrbios | |
| BRPI1013927A2 (pt) | métodos e composições para o tratamento de lúpus | |
| BRPI0810171A2 (pt) | Método para o aumento da secreção de insulina | |
| BRPI0921410A2 (pt) | material resistente à penetração |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |